Search results for "Primary prevention"

showing 10 items of 89 documents

Impact of maternal body mass index and gestational weight gain on pregnancy complications: an individual participant data meta-analysis of European, …

2019

ObjectiveTo assess the separate and combined associations of maternal pre‐pregnancy body mass index (BMI) and gestational weight gain with the risks of pregnancy complications and their population impact.DesignIndividual participant data meta‐analysis of 39 cohorts.SettingEurope, North America, and Oceania.Population265 270 births.MethodsInformation on maternal pre‐pregnancy BMI, gestational weight gain, and pregnancy complications was obtained. Multilevel binary logistic regression models were used.Main outcome measuresGestational hypertension, pre‐eclampsia, gestational diabetes, preterm birth, small and large for gestational age at birth.ResultsHigher maternal pre‐pregnancy BMI and gesta…

Gestational hypertensionand promotion of well-beingNutrition and DiseaseBirthweightReproductive health and childbirthLow Birth Weight and Health of the NewbornCardiovascularMedical and Health SciencesDISEASECohort Studies0302 clinical medicine3123 Gynaecology and paediatricsRisk FactorsPregnancyVoeding en ZiekteInfant MortalityOdds RatioMedicineBirth Weight2.1 Biological and endogenous factorsEPIDEMIOLOGYwq_200Aetiology2. Zero hungerPediatricRISKeducation.field_of_studyOUTCOMES030219 obstetrics & reproductive medicineObstetricspregnancy complicationsDiabetesObstetrics and GynecologyGestational ageweight gainASSOCIATIONGestational Weight GainGestational diabetesEuropeBirthweight ; Body Mass Index ; Pregnancy Complications ; Preterm Birth ; Weight GainOBESITYFemalemedicine.symptomAdultmedicine.medical_specialtyPRETERM BIRTHBirth weightPopulationGestational Agebody mass index[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricswa_310Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterPretermClinical ResearchHumanswq_100ObesityeducationObstetrics & Reproductive MedicineMetabolic and endocrineNutritionPregnancybusiness.industryContraception/ReproductionPreventionBirthweight; body mass index; pregnancy complications; preterm birth; weight gainAustraliaInfantbirth weightpreterm birthDIABETES-MELLITUSPreterm birth weight gainOverweightPerinatal Period - Conditions Originating in Perinatal Periodmedicine.diseaseNewbornPrevention of disease and conditionsReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Good Health and Well BeingNorth America3.1 Primary prevention interventions to modify behaviours or promote wellbeingpregnancy complicationbusinessWeight gainBody mass indexwb_200
researchProduct

Human papillomavirus-associated cancers: a survey on otorhinolaryngologists' knowledge and attitudes on prevention.

2016

Human papillomavirus (HPV) infection is a recognised causal factor associated with oropharyngeal cancers. The global burden of HPVrelated oropharyngeal cancers is on the increase and is predicted to surpass the burden of cervical cancer in the near future. As evidence is accumulating on the potential effectiveness of an HPV vaccine in controlling the oropharyngeal cancer epidemic; otorhinolaryngologists assume a key role - not only in the diagnosis and treatment of HPV-related cancers - but also in educating and advocating on HPV prevention. We conducted a survey to assess Italian otorhinolaryngologists' knowledge and attitudes regarding HPV infection, HPV-related oropharyngeal diseases and…

Health Knowledge Attitudes PracticeHuman papillomavirusPrimary preventionHead and Neck NeoplasmPapillomavirus InfectionsEuropeOtolaryngologyHuman papillomaviruKnowledgeItalyHead and Neck NeoplasmsNeoplasmsSurveys and QuestionnairesHumansFemalePapillomavirus VaccinesPapillomavirus VaccineHead and NeckActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
researchProduct

iViaggio: the app for safe traveling.

2019

he number of people travelling internationally increases year after year, mainly due to the more and more affordable cost of travelling and to the evergreater ease of transportation. Nowadays, any destination can be reached within 24 hours by plane, and the improvement of economic conditions facilitates both business and leisure travelling, as a matter of fact, according to data from the World Tourism Organization, the number of international trips is expected to increase by 3% to 4% per year.1 However, international travelling poses various health risks depending on travelers’ health conditions and the type of trip undertaken. Indeed, travelers may experience sudden changes in altitude, hu…

Infection ControlHistoryDatabases FactualVaccinationGeneral MedicineGlobal HealthMobile ApplicationsVaccinazioniPrimary PreventionHumansSmartphoneSafetyTravel-Related IllnessRisk Reduction BehaviorMinerva medica
researchProduct

VALUTAZIONE DELLA PROTEINA C-REATTIVA AD ELEVATA SENSIBILITÀ IN PREVENZIONE PRIMARIA

2007

In an attempt to improve global cardiovascular risk prediction, considerable interest has focused on C-reactive protein (CRP), that has been shown in multiple prospective epidemiological studies to predict incident myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death. CRP is a hepatically-derived pentraxin that plays a key role in the innate immune response. Standard CRP tests determine levels which are increased up to 1000-fold in response to infection or tissue destruction, but cannot adequately assess the normal range. High-sensitive CRP detects levels of CRP within the normal range as well as higher levels proven to predict future cardiovascular events. T…

InflammationPrimary preventionAtherosclerosiPROTEINA C-REATTIVA AD ELEVATA SENSIBILITÀ PREVENZIONE PRIMARIA
researchProduct

Prevention of Hepatocellular Carcinoma

2005

The accuracy and the reliability of well-recognized clinical, virologic, histologic, and molecular risk factors for HCC are still insufficient; thus, accurate risk prediction of developing cancer in individual patients remains an elusive goal. Future directions in chemprevention of HCC will be on the development of molecular risk models and of new chemopreventive agents. The design of targeted molecular therapies may need to be tailored to the specific molecular phenotype of a specific HCC. Studies examining multiple genes and proteins (genomics and proteomics) in the same HCCs will be required to evaluate this possibility thoroughly. In the setting of primary prevention, the epidemiologic …

Liver CirrhosisMaleadefovirOncologymedicine.medical_specialtyCarcinoma HepatocellularAntiviral AgentsRisk AssessmentSensitivity and SpecificityGastroenterologyHepatitis B Chronicpolyprenoic acidretinoidInternal medicinemedicineHumansMass Screeningantineoplastic agentReliability (statistics)Randomized Controlled Trials as TopicHepatologybusiness.industryLiver NeoplasmsCancerinterferonHepatitis C ChronicPrognosismedicine.diseaseSurvival AnalysisPrimary Preventionhepatitis C vaccineHepatocellular carcinomaFemaleInterferonslamivudinebusinesshepatitis B vaccineClinics in Liver Disease
researchProduct

Treating eating disorders in the real world — MaiStep: A skill-based universal prevention for schools

2019

Eating disorders are difficult to treat and often associated with morbidity and mortality. Universal prevention approaches are increasingly focusing on enhancing skills, but few eating disorder programs are available for under-15-year-olds. This study aimed to develop and examine a school-based universal prevention program ('MaiStep') for adolescent boys and girls. A three-arm randomized controlled trial with baseline, post-intervention and 12-month follow-up was conducted with 1654 adolescents (M = 13.35, SD 0.76). 'MaiStep' was delivered by psychologists in the first intervention group (IG1) and teachers in the second intervention group (IG2), and compared to an active control group (ACG)…

MaleAdolescentEpidemiologyGlobal HealthAnorexia nervosaAffect (psychology)Risk Assessment01 natural scienceslaw.inventionFeeding and Eating Disorders03 medical and health sciences0302 clinical medicineRandomized controlled triallawGermanyBody ImagemedicineHumans030212 general & internal medicineDrive for thinness0101 mathematics610 Medicine & healthHealth EducationRandomized Controlled Trials as TopicSchool Health Servicesbusiness.industry010102 general mathematicsPublic Health Environmental and Occupational HealthUniversal preventionCognitionmedicine.diseasePrimary PreventionClinical trialEating disordersTreatment OutcomeFemalebusinessClinical psychologyPreventive Medicine
researchProduct

''Assessment of the use of hypolipidemic agents (HAs), mainly statins, in elderly subjects aged 80 years and more in Burgundy: Analysis of 13,211 pat…

2012

Manckoundia, Patrick | Lorenzini, Mathieu | Disson-Dautriche, Anne | Petit, Jean-Michel | Lorcerie, Bernard | Debost, Emmanuel | Menu, Didier | Pfitzenmeyer, Pierre; International audience; ''Only few studies have investigated the use of HA in elderly subjects and there are no data in very elderly subjects. We assessed the prescription of HA and analyzed the relationship between such prescriptions and frailty markers among persons aged 80 and more in an observational study. We recorded the prescriptions for 13,211 patients aged 80-109 years and affiliated to the "Mutualite-Sociale-Agricole (MSA)'' of Burgundy over a 1-month period. The prescription of a HA among all included patients, and t…

MaleAgingHealth (social science)DiseaseCoronary Artery Disease030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawAVERAGE CHOLESTEROL LEVELS030212 general & internal medicineStrokeHypolipidemic AgentsAged 80 and overFibric AcidsOPEN-LABEL3. Good healthCONTROLLED TRIALHypertensionFemaleFranceSTROKEmedicine.drugmedicine.medical_specialtyAdrenergic beta-AntagonistsDrug Prescriptions03 medical and health sciencesPeripheral Arterial DiseaseDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansCORONARY-HEART-DISEASEMedical prescriptionCARDIOVASCULAR EVENTSMORTALITY''Polypharmacybusiness.industryMORTALITY[SCCO.NEUR]Cognitive science/NeuroscienceCardiovascular Agentsmedicine.disease''CORONARY-HEART-DISEASEPRAVASTATINPhysical therapyPolypharmacyRISK-FACTORSObservational studyGeriatrics and GerontologyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPRIMARY PREVENTIONGerontologyPravastatinPlatelet Aggregation Inhibitors
researchProduct

Global, regional, and national burden of stroke, 1990-2016

2019

Background: Stroke is a leading cause of mortality and disability worldwide and the economic costs of treatment and post-stroke care are substantial. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic, comparable method of quantifying health loss by disease, age, sex, year, and location to provide information to health systems and policy makers on more than 300 causes of disease and injury, including stroke. The results presented here are the estimates of burden due to overall stroke and ischaemic and haemorrhagic stroke from GBD 2016. Methods: We report estimates and corresponding uncertainty intervals (UIs), from 1990 to 2016, for incidence, preval…

MaleCost effectivenessIMPACTGlobal HealthGUIDELINES3124 Neurology and psychiatryBrain IschemiaGlobal Burden of DiseaseCOST-EFFECTIVENESS0302 clinical medicineRisk FactorsGlobal healthPrevalenceMedicine030212 general & internal medicineStrokePOPULATIONAged 80 and overRISKeducation.field_of_studyIncidence (epidemiology)Mortality rateIncidenceAge FactorsMiddle AgedPREVALENCEStrokeFemaleLife Sciences & BiomedicineIntracranial HemorrhagesAdultPopulationClinical Neurology03 medical and health sciencesHumanseducationAgedScience & TechnologyNeurology & Neurosurgerybusiness.industry3112 NeurosciencesKlinisk medicin1103 Clinical Sciencesmedicine.diseaseGBD 2016 Stroke CollaboratorsVerbal autopsyTRANSIENT ISCHEMIC ATTACKYears of potential life lostSocioeconomic FactorsHuman medicineNeurosciences & NeurologyNeurology (clinical)Clinical Medicine1109 NeurosciencesbusinessPRIMARY PREVENTION030217 neurology & neurosurgeryDemographyRCLancet Neurology
researchProduct

Refined Analysis of the Critical Age Ranges of Childhood Overweight: Implications for Primary Prevention

2012

Prevention-interventions would certainly benefit from a precise knowledge of the age range when the most pronounced increases in prevalence of overweight and obesity occur in the general population. Data of 15,662 subjects aged 2-18 years were obtained from a national representative health survey (German Health Interview and Examination Survey for Children and Adolescents (KiGGS)) conducted in Germany. Weight, height, and BMI z-scores were calculated relative to the UK 1990 reference, and prevalence of overweight and obesity was defined according to the IOTF (International Obesity Task Force) age- and sex-specific cut-offs. Univariate ANOVAs for overweight, obesity, weight, height, and BMI …

MaleGerontologyAdolescentCross-sectional studyCost-Benefit AnalysisEndocrinology Diabetes and MetabolismPopulationMedicine (miscellaneous)OverweightBody Mass Indexsymbols.namesakeSex FactorsEndocrinologyReference ValuesGermanyPrevalencemedicineHumansObesityChildeducationAnalysis of Varianceeducation.field_of_studyNutrition and Dieteticsbusiness.industryBody WeightAge FactorsInfant NewbornInfantmedicine.diseaseObesityPrimary PreventionCross-Sectional StudiesBonferroni correctionChild PreschoolsymbolsFemaleAnalysis of variancemedicine.symptombusinessPsychosocialBody mass indexDemographyObesity
researchProduct

Overview of the benefitsand potential issues of the nonavalent HPV vaccine

2017

HPV-related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are examined. Efficacy data come from a pivotal trial, which was conducted among women aged 16–26 years randomly assigned to receive either the 9vHP…

MaleHPVmedicine.medical_specialtyUterine Cervical NeoplasmsDiseaseAnatomic region03 medical and health sciences0302 clinical medicineHPV nonavalent vaccinePrimary preventionEnvironmental healthmedicineHumansPapillomavirus Vaccines030212 general & internal medicineCervical cancer; HPV; HPV nonavalent vaccine; Prevention; Female; Humans; Male; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; Randomized Controlled Trials as Topic; Uterine Cervical NeoplasmsPapillomaviridaeRandomized Controlled Trials as TopicGynecologyCervical cancerbusiness.industryPreventionPapillomavirus InfectionsObstetrics and GynecologyHpv vaccinationGeneral Medicinemedicine.disease030220 oncology & carcinogenesisCervical cancer; HPV; HPV nonavalent vaccine; PreventionCervical cancerFemalebusiness
researchProduct